BSE Live
Feb 03, 14:28Prev. Close
1915.15
Open Price
1956.35
Bid Price (Qty.)
1950.80 (3)
Offer Price (Qty.)
1953.95 (19)
NSE Live
Feb 03, 14:28Prev. Close
1920.40
Open Price
1995.00
Bid Price (Qty.)
1951.60 (5)
Offer Price (Qty.)
1952.10 (5)
| Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 23.72 | 11.85 | |
| Total Share Capital | 43.72 | 21.85 | |
| Reserves and Surplus | 285.20 | 212.51 | |
| Total Reserves and Surplus | 285.20 | 212.51 | |
| Total Shareholders Funds | 328.96 | 234.36 | |
| Minority Interest | 0.00 | 0.44 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 408.98 | 114.87 | |
| Deferred Tax Liabilities [Net] | 38.61 | 29.32 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 447.60 | 144.19 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 27.87 | 0.00 | |
| Trade Payables | 74.97 | 0.00 | |
| Other Current Liabilities | 28.16 | 72.77 | |
| Short Term Provisions | 9.71 | 3.97 | |
| Total Current Liabilities | 140.71 | 76.74 | |
| Total Capital And Liabilities | 917.27 | 455.74 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 178.22 | 148.97 | |
| Intangible Assets | 159.00 | 0.00 | |
| Capital Work-In-Progress | 13.06 | 25.19 | |
| Fixed Assets | 350.28 | 174.15 | |
| Non-Current Investments | 15.21 | 14.75 | |
| Deferred Tax Assets [Net] | 7.70 | 2.82 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 1.96 | 3.01 | |
| Total Non-Current Assets | 375.15 | 194.72 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 119.42 | 82.16 | |
| Trade Receivables | 237.56 | 130.48 | |
| Cash And Cash Equivalents | 127.28 | 8.13 | |
| Short Term Loans And Advances | 57.87 | 40.25 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 542.12 | 261.01 | |
| Total Assets | 917.27 | 455.74 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 0.46 | 5.11 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 15.84 | 3.98 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | 0.86 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 15.17 | 14.71 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 |
03.02.2026
Glenmark Standalone December 2025 Net Sales at Rs 2,359.94 crore, up 4.83% Y-o-Y
05.01.2026
Chartist Talk: Avoid Vodafone Idea; Escorts Kubota, Glenmark set for breakout, says Milan Vaishnav
04.01.2026
23.12.2025
03.02.2026
Glenmark Standalone December 2025 Net Sales at Rs 2,359.94 crore, up 4.83% Y-o-Y
04.12.2025
Glenmark Consolidated September 2025 Net Sales at Rs 6,046.87 crore, up 76.1% Y-o-Y
24.11.2025
Glenmark Standalone September 2025 Net Sales at Rs 1,538.66 crore, down 41.63% Y-o-Y
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015